Wendy C King1, Jia-Yuh Chen2, Anita P Courcoulas3, Gregory F Dakin4, Scott G Engel5, David R Flum6, Marcelo W Hinojosa6, Melissa A Kalarchian7, Samer G Mattar8, James E Mitchell5, Alfons Pomp4, Walter J Pories9, Kristine J Steffen10, Gretchen E White11, Bruce M Wolfe12, Susan Z Yanovski13. 1. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. Electronic address: kingw@edc.pitt.edu. 2. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 3. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 4. Weill Cornell Medical College, New York, New York. 5. Neuropsychiatric Research Institute, Fargo, North Dakota. 6. Department of Surgery, University of Washington, Seattle, Washington. 7. Department of Psychiatry, University of Pittsburgh School of Medicine, and Duquesne University School of Nursing, Pittsburgh, Pennsylvania. 8. Department of Surgery, Oregon Health Sciences University, Portland, Oregon. 9. Department of Surgery, Brody School of Medicine, East Carolina University, Greenville, North Carolina. 10. Neuropsychiatric Research Institute, Fargo, North Dakota; Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota. 11. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 12. Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota. 13. Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
Abstract
BACKGROUND: Empirical evidence suggests Roux-en-Y gastric bypass (RYGB) increases risk of developing alcohol use disorder (AUD). However, prospective assessment of substance use disorders (SUD) after bariatric surgery is limited. OBJECTIVE: To report SUD-related outcomes after RYGB and laparoscopic adjustable gastric banding (LAGB). To identify factors associated with incident SUD-related outcomes. SETTING: 10 U.S. hospitals METHODS: The Longitudinal Assessment of Bariatric Surgery-2 is a prospective cohort study. Participants self-reported past-year AUD symptoms (determined by the Alcohol Use Disorders Identification Test), illicit drug use (cocaine, hallucinogens, inhalants, phencyclidine, amphetamines, or marijuana), and SUD treatment (counseling or hospitalization for alcohol or drugs) presurgery and annually postsurgery for up to 7 years through January 2015. RESULTS: Of 2348 participants who underwent RYGB or LAGB, 2003 completed baseline and follow-up assessments (79.2% women, baseline median age: 47 years, median body mass index 45.6). The year-5 cumulative incidence of postsurgery onset AUD symptoms, illicit drug use, and SUD treatment were 20.8% (95% confidence interval (CI): 18.5-23.3), 7.5% (95% CI: 6.1-9.1), and 3.5% (95% CI: 2.6-4.8), respectively, post-RYGB, and 11.3% (95% CI: 8.5-14.9), 4.9% (95% CI: 3.1-7.6), and .9% (95% CI: .4-2.5) post-LAGB. Undergoing RYGB versus LAGB was associated with higher risk of incident AUD symptoms (adjusted hazard ratio or AHR = 2.08 [95% CI: 1.51-2.85]), illicit drug use (AHR = 1.76 [95% CI: 1.07-2.90]) and SUD treatment (AHR = 3.56 [95% CI: 1.26-10.07]). CONCLUSIONS: Undergoing RYGB versus LAGB was associated with twice the risk of incident AUD symptoms. One-fifth of participants reported incident AUD symptoms within 5 years post-RYGB. AUD education, screening, evaluation, and treatment referral should be incorporated in pre- and postoperative care.
BACKGROUND: Empirical evidence suggests Roux-en-Y gastric bypass (RYGB) increases risk of developing alcohol use disorder (AUD). However, prospective assessment of substance use disorders (SUD) after bariatric surgery is limited. OBJECTIVE: To report SUD-related outcomes after RYGB and laparoscopic adjustable gastric banding (LAGB). To identify factors associated with incident SUD-related outcomes. SETTING: 10 U.S. hospitals METHODS: The Longitudinal Assessment of Bariatric Surgery-2 is a prospective cohort study. Participants self-reported past-year AUD symptoms (determined by the Alcohol Use Disorders Identification Test), illicit drug use (cocaine, hallucinogens, inhalants, phencyclidine, amphetamines, or marijuana), and SUD treatment (counseling or hospitalization for alcohol or drugs) presurgery and annually postsurgery for up to 7 years through January 2015. RESULTS: Of 2348 participants who underwent RYGB or LAGB, 2003 completed baseline and follow-up assessments (79.2% women, baseline median age: 47 years, median body mass index 45.6). The year-5 cumulative incidence of postsurgery onset AUD symptoms, illicit drug use, and SUD treatment were 20.8% (95% confidence interval (CI): 18.5-23.3), 7.5% (95% CI: 6.1-9.1), and 3.5% (95% CI: 2.6-4.8), respectively, post-RYGB, and 11.3% (95% CI: 8.5-14.9), 4.9% (95% CI: 3.1-7.6), and .9% (95% CI: .4-2.5) post-LAGB. Undergoing RYGB versus LAGB was associated with higher risk of incident AUD symptoms (adjusted hazard ratio or AHR = 2.08 [95% CI: 1.51-2.85]), illicit drug use (AHR = 1.76 [95% CI: 1.07-2.90]) and SUD treatment (AHR = 3.56 [95% CI: 1.26-10.07]). CONCLUSIONS: Undergoing RYGB versus LAGB was associated with twice the risk of incident AUD symptoms. One-fifth of participants reported incident AUD symptoms within 5 years post-RYGB. AUD education, screening, evaluation, and treatment referral should be incorporated in pre- and postoperative care.
Authors: Steven H Belle; Paul D Berk; Anita P Courcoulas; David R Flum; Carolyn W Miles; James E Mitchell; Walter J Pories; Bruce M Wolfe; Susan Z Yanovski Journal: Surg Obes Relat Dis Date: 2007 Mar-Apr Impact factor: 4.734
Authors: Per-Arne Svensson; Åsa Anveden; Stefano Romeo; Markku Peltonen; Sofie Ahlin; Maria Antonella Burza; Björn Carlsson; Peter Jacobson; Anna-Karin Lindroos; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Kajsa Sjöholm; Hans Wedel; Bo Söderpalm; Lars Sjöström; Lena M S Carlsson Journal: Obesity (Silver Spring) Date: 2013-05-31 Impact factor: 5.002
Authors: Christine E Spadola; Eric F Wagner; Frank R Dillon; Mary Jo Trepka; Nestor De La Cruz-Munoz; Sarah E Messiah Journal: Alcohol Clin Exp Res Date: 2015-08-04 Impact factor: 3.455
Authors: Wendy C King; Jia-Yuh Chen; Steven H Belle; Anita P Courcoulas; Gregory F Dakin; Katherine A Elder; David R Flum; Marcelo W Hinojosa; James E Mitchell; Walter J Pories; Bruce M Wolfe; Susan Z Yanovski Journal: JAMA Date: 2016-04-05 Impact factor: 56.272
Authors: María Belén Acevedo; J Christopher Eagon; Bruce D Bartholow; Samuel Klein; Kathleen K Bucholz; Marta Yanina Pepino Journal: Surg Obes Relat Dis Date: 2017-11-10 Impact factor: 4.734
Authors: María Belén Acevedo; Margarita Teran-Garcia; Kathleen K Bucholz; J Christopher Eagon; Bruce D Bartholow; Nicholas A Burd; Naiman Khan; Blair Rowitz; Marta Yanina Pepino Journal: Surg Obes Relat Dis Date: 2020-01-23 Impact factor: 4.734
Authors: Alan C Spector; Natasha Kapoor; Ruth K Price; M Yanina Pepino; M Barbara E Livingstone; Carel W Le Roux Journal: Chem Senses Date: 2019-03-11 Impact factor: 3.160
Authors: Christine E Spadola; Eric F Wagner; Leah M Varga; Jennifer L Syvertsen; Nestor F De La Cruz Munoz; Sarah E Messiah Journal: Obes Surg Date: 2018-10 Impact factor: 4.129
Authors: Gretchen E White; Anita P Courcoulas; Wendy C King; David R Flum; Susan Z Yanovski; Alfons Pomp; Bruce M Wolfe; Konstantinos Spaniolas; Walter Pories; Steven H Belle Journal: Surg Obes Relat Dis Date: 2019-08-26 Impact factor: 4.734
Authors: Thomas H Inge; Anita P Courcoulas; Todd M Jenkins; Marc P Michalsky; Mary L Brandt; Stavra A Xanthakos; John B Dixon; Carroll M Harmon; Mike K Chen; Changchun Xie; Mary E Evans; Michael A Helmrath Journal: N Engl J Med Date: 2019-05-16 Impact factor: 91.245
Authors: Nadine Ibrahim; Mitchell Alameddine; Julia Brennan; Michael Sessine; Charles Holliday; Amir A Ghaferi Journal: Surg Endosc Date: 2018-10-22 Impact factor: 4.584
Authors: Kathryn E Smith; Scott G Engel; Kristine J Steffen; Luis Garcia; Karen Grothe; Afton Koball; James E Mitchell Journal: Obes Surg Date: 2018-05 Impact factor: 4.129